Literature DB >> 8719145

Monitoring interval cancers in breast screening programmes: the east Anglian experience. Quality Assurance Management Group of the East Anglian Breast Screening Programme.

N Day1, J McCann, C Camilleri-Ferrante, P Britton, G Hurst, S Cush, S Duffy.   

Abstract

Interval cancer rates are a major determinant of the success of a screening programme. In the Swedish two county study, on which the United Kingdom programme is based, a 39% reduction in mortality was observed in screened women aged 50-64. Using data from the Swedish study, the relationship between interval cancer incidence and the likely future effect on breast cancer mortality was quantified. In East Anglia, as elsewhere in the United Kingdom, interval cancers rates are nearly double those obtained in Sweden: interval cancer rates in the first, second, and third years respectively, after a negative screen were 24%, 59%, and 79% of the expected underlying incidence in the absence of screening. The corresponding figures from the two county study were 17%, 30%, and 56%. From these it was estimated that the mortality reduction in East Anglia will be 21%, which is lower than the 35% observed in invited women in this age group in the Swedish two county study and the 25% specified in the Health of the Nation target. In a rereading exercise, using screening mammograms from women who were screen normal, who had screen detected cancers, or who subsequently developed interval cancers, four out of five radiologists recommended recall for around 70% of the original mammograms (classed as screen normal at time of screening) from 33 interval cancers. This suggests that sensitivity is a contributory factor to the higher interval cancer rates in East Anglia.

Entities:  

Mesh:

Year:  1995        PMID: 8719145     DOI: 10.1177/096914139500200402

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  15 in total

Review 1.  Is clinical breast examination an acceptable alternative to mammographic screening?

Authors:  I Mittra; M Baum; H Thornton; J Houghton
Journal:  BMJ       Date:  2000-10-28

2.  NHS breast screening programme. Both extended age range and reduced screening interval are needed.

Authors:  H Goodare; M King
Journal:  BMJ       Date:  1999-02-06

3.  Survival rates from interval cancer in NHS breast screening programme.

Authors:  S Collins; C B Woodman; A Threlfall; P Prior
Journal:  BMJ       Date:  1998-03-14

4.  NHS breast screening programme: is the high incidence of interval cancers inevitable?

Authors:  D Asbury; C R Boggis; D Sheals; A G Threlfall; C B Woodman
Journal:  BMJ       Date:  1996-11-30

5.  Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group.

Authors:  S Moss; R Blanks
Journal:  J Epidemiol Community Health       Date:  1998-02       Impact factor: 3.710

6.  A study of interval breast cancer within the NHS breast screening programme.

Authors:  W K Cowan; B Angus; J C Gray; L G Lunt; S R al-Tamimi
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

7.  Breast Cancer Screening in Asian Women with Dense Breast by Mammography: A Cross-Sectional Observational Study.

Authors:  Jung Sun Lee; Minkyung Oh
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

8.  Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland.

Authors:  R L Bennett; S J Sellars; S M Moss
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

9.  Performance of papanicolaou testing and detection of cervical carcinoma in situ in participants of organized cervical cancer screening in South Korea.

Authors:  Mi Ah Han; Kui Son Choi; Hoo-Yeon Lee; Jae Kwan Jun; Kyu Won Jung; Sokbom Kang; Eun-Cheol Park
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

10.  Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02).

Authors:  D G Evans; S Thomas; J Caunt; L Roberts; A Howell; M Wilson; R Fox; D M Sibbering; S Moss; M G Wallis; D M Eccles; S Duffy
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.